Why Depression Rates Are Rising Despite Better Treatment
June 11, 2026 · Frisian News
Depression diagnoses have tripled since 2000, yet more people report being depressed. The industry profits from treatment, not recovery.
Depression diagnoses in wealthy countries have tripled since 2000, yet prescriptions for antidepressants have also climbed. Sweden recorded over 800,000 people on psychiatric medication in 2024, double the number from 2010. If treatment works, why do more people report being depressed?
Pharmaceutical companies profit from diagnosis and scale. A depressed patient is a customer for life. The industry funds most research into depression and has every incentive to widen the definition, lower diagnostic thresholds, and extend treatment duration. When Pfizer or Eli Lilly funds a study, the outcome is rarely that pills don't help. The business model rewards disorder, not recovery.
The actual problem is not that we lack medication. It is that our lives have become more isolated, more uncertain, more atomized. Work has become precarious. Communities have collapsed. Children spend hours on screens instead of playing outside. We moved from village life to digital solitude. No pill fixes that. A depressed person in a functioning community might recover through meaning, purpose, and belonging. Those things cannot be patented.
Governments and tech companies have every reason to promote the medical model. If depression is a brain disease requiring pills, the solution is individual treatment, not social reconstruction. If it is a symptom of broken communities and lost meaning, the answer is painful and political. It is easier to prescribe fluoxetine than to rebuild what was lost. It is cheaper for the state to pay for medication than to fund local institutions, family, and civic life.
The treatment is getting better. The problem is getting worse. That should tell us something. We are treating the wrong illness with the wrong solution.
Published June 11, 2026 · Frisian News